tbuckley/cabot-search huggingface dataset:
Abstract 9470: The Relative Risk of Cerebrovascular Accident in Patients With Von-Willebrand Disease
Authors: Abdulbaril Olagunju, Nawfal Mihyawi, Ayman R Fath, Beani Forst, Bikash Bhattarai, Beeletsega T Yeneneh
Journal: Circulation (2021)

Introduction: Von Willebrand factor (vWF) is essential in platelet adhesion and aggregation. High concentration of vWF is associated with cerebrovascular accidents (CVA); however, it is yet unclear if its deficiency could protect against CVA. This study aims to compare the prevalence and relative risk (RR) of CVA in patients with and without vWD. Methods: Discharge data of the National Inpatient Sample (NIS) from 2009 to 2014 were analyzed and records for vWD and CVA were identified using ICD-9 codes. Log-binomial model was used to estimate the RR of CVA in patients with and without vWD after adjustment for CVA risk factors. Results: A total of 224,475,443 weight adjusted hospital discharge sample of patients, including 82,809 patients with vWD, were identified. The prevalence of CVA was lower in patients with vWD than those without vWD (1.31% vs 2.04%), with a RR of 0.64 (95% CI: 0.60-0.68) (table 1). Adjusted RR for CVA risk factors was 0.71 (95% CI: 0.67-0.76) (table 2). Conclusion: Patients with vWD showed a lower risk of developing CVA when compared to those without vWD, this lower RR persisted after controlling for other CVA risk factors. These findings suggest that vWD could be protective against CVA, and vWF might be a potential therapeutic target that requires further investigation in individuals at high risk of developing CVA.
Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy
Authors: Blessie Elizabeth Nelson, Jeremy L. Ramdial, Qaiser Bashir, Neeraj Saini, Chitra Hosing, Uday R. Popat, Ruby Delgado, Hans C. Lee, Gregory P. Kaufman, Robert Z. Orlowski, Richard E. Champlin, Muzaffar H. Qazilbash, Samer A. Srour
Journal: Blood (2021)
Amino Acid Stress Response Genes Promote L-Asparaginase Resistance in Pediatric Acute Lymphoblastic Leukemia
Authors: Daniel Ferguson, J. Robert McCorkle, Qian Dong, Erik Bonten, Wenjian Yang, Brennan P. Bergeron, Robert J Autry, Jonathan Diedrich, Yoshihiro Gocho, Richa Bajpai, Kristine R. Crews, Shondra M. Pruett-Miller, Kathryn G Roberts, Wendy Stock, Charles G. Mullighan, Hiroto Inaba, Sima Jeha, Ching-Hon Pui, Jun J. Yang, Mary V. Relling, William E. Evans, Daniel Savic
Journal: Blood (2021)
The colonial overtones of overseas electives should make us rethink this practice
Authors: Will Smith
Journal: BMJ (2021)

Since the outbreak of covid-19, overseas electives have been placed indefinitely on hold for UK medical students. With ever changing guidelines on social contact, health systems under intense pressure, and shifting rules on travel, universities are no longer able to sanction students travelling outside of the UK to complete their elective placements. This pause should provide us with an opportunity to consider whether the seemingly obvious advantages of overseas electives for future doctors can be justified, when in truth they hold both potential for harm and an underlying sentiment that is somewhat troubling.

Many UK medical students, as well as medical educators, will undoubtedly be disappointed by what is, to all intents and purposes, another sad casualty of this pandemic. But it’s not just about students looking for that next high yield, “in real life” learning experience. In the General Medical Council’s own Outcomes for Graduates , they state that as part of their education, future doctors should “describe and illustrate from their own professional experience the range of settings in which patients receive care, including in the community, in patients’ homes, and in primary and secondary care provider settings.”1 Although it …
A Validated Risk Prediction Model for Bone Fragility in Children with Acute Lymphoblastic Leukemia
Authors: Emma Jacobine Verwaaijen, Jinhui Ma, Hester A. De Groot-Kruseman, Rob Pieters, Inge M. Van Der Sluis, Jenneke E. Van Atteveld, Jacqueline Halton, Conrad Fernandez, Annelies Hartman, Robert de Jonge, Maarten Lequin, Mariël L. te Winkel, Stephanie A. Atkinson, Nathalie Alos, Ronald Barr, Ronald M. Grant, John Hay, Adam Huber, Josephine Ho, Jacob Jaremko, Khaldoun Koujok, Bianca Lang, Mary-Ann Matzinger, Nazih Shenouda, Frank Rauch, Celia Rodd, Marry M. van den Heuvel-Eibrink, Saskia M.F. Pluijm, Leanne Ward
Journal: Blood (2021)
Benefits of a Disease Management Program for SCD in Germany 2011 - 2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome
Authors: Joachim B. Kunz, Andreas Schlotmann, Andrea Daubenbüchel, Stephan Lobitz, Andrea Jarisch, Regine Grosse, Holger Cario, Lena Oevermann, Dani Hakimeh, Laura Tagliaferri, Andreas E. Kulozik
Journal: Blood (2021)
Addressing Racism in Preventive Services
Authors: Jennifer S. Lin, Lynn Hoffman, Sarah I. Bean, Elizabeth A. O’Connor, Allea M. Martin, Megan O. Iacocca, Olivia P. Bacon, Melinda C. Davies
Journal: JAMA (2021)

In January 2021, the US Preventive Services Task Force (USPSTF) issued a values statement that acknowledged systemic racism and included a commitment to address racism and health equity in recommendations for clinical preventive services.To articulate the definitional and conceptual issues around racism and health inequity and to describe how racism and health inequities are currently addressed in preventive health.An audit was conducted assessing (1) published literature on frameworks or policy and position statements addressing racism, (2) a subset of cancer and cardiovascular topics in USPSTF reports, (3) recent systematic reviews on interventions to reduce health inequities in preventive health or to prevent racism in health care, and (4) health care-relevant professional societies, guideline-making organizations, agencies, and funding bodies to gather information about how they are addressing racism and health equity.Race as a social category does not have biological underpinnings but has biological consequences through racism. Racism is complex and pervasive, operates at multiple interrelated levels, and exerts negative effects on other social determinants and health and well-being through multiple pathways. In its reports, the USPSTF has addressed racial and ethnic disparities, but not racism explicitly. The systematic reviews to support the USPSTF include interventions that may mitigate health disparities through cultural tailoring of behavioral interventions, but reviews have not explicitly addressed other commonly studied interventions to increase the uptake of preventive services or foster the implementation of preventive services. Many organizations have issued recent statements and commitments around racism in health care, but few have provided substantive guidance on operational steps to address the effects of racism. Where guidance is unavailable regarding the proposed actions, it is principally because work to achieve them is in very early stages. The most directly relevant and immediately useful guidance identified is that from the GRADE working group.This methods report provides a summary of issues around racism and health inequity, including the status of how these are being addressed in preventive health.
Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk
Authors: Laura Duran-Lozano, Gudmar Thorleifsson, Aitzkoa Lopez de Lapuente Portilla, Abhishek Niroula, Molly Went, Malte Thodberg, Maroulio Pertesi, Ram Ajore, Caterina Cafaro, Pall I. Olason, Lilja Stefansdottir, G. Bragi Walters, Gisli H. Halldorsson, Ingemar Turesson, Martin F. Kaiser, Niels Weinhold, Niels Abildgaard, Niels Frost Andersen, Ulf-Henrik Mellqvist, Anders Waage, Annette Juul-Vangsted, Unnur Thorsteinsdottir, Markus Hansson, Richard Houlston, Thorunn Rafnar, Kari Stefansson, Björn Nilsson
Journal: Blood Cancer Journal (2021)
Molecular and MRD-Based Characterization of Acute Lymphoblastic Leukemia in Mexico: Experience from the <i>Mexico in Alliance with St. Jude</i> "Bridge Project"
Authors: Dinora Virginia Aguilar, Pablo Gonzalez-Montalvo, Hugo Romo, Daniela Arce, Margarita Gonzalez-Zamorano, Mayra Ivette Lopez-Ruiz, José De Jesús Loeza Oliva, Nataly Mercado, Naomi Echeandia, Karla Nohemi Guerrero Gómez, Lourdes Vega, Sergio Garay, Martha Fabiola Castro, Berenice Jarquín-Ramirez, Elizabeth Candy Ramírez-Martinez, Víctor Manuel Ortiz-Gálvez, Netzi Rivera-Sanchez, Carlos Rodriguez-Galindo, Paola M. Friedrich
Journal: Blood (2021)
Pembrolizumab in Combination with Antigen-Specific Cytotoxic T Lymphocytes Enhances Killing of Acute Myeloid Leukemia
Authors: Amber Gibson, Mao Zhang, Pariya Sukhumalchandra, Anne V. Philips, Na Qiao, Alexander A. Perakis, Celine Kerros, Lisa St. John, Karen Clise-Dwyer, Sijie Lu, Qing Ma, Jeffrey J. Molldrem, Gheath Alatrash
Journal: Blood (2021)
Graded Renal Response Criteria for Light Chain (AL) Amyloidosis
Authors: Eli Muchtar, Brendan Wisniowski, Giovanni Palladini, Paolo Milani, Giampaolo Merlini, Stefan Schönland, Kaya Veelken, Ute Hegenbart, Angela Dispenzieri, Shaji Kumar, Nelson Leung, Efstathios Kastritis, Meletios A. Dimopoulos, Michaela Liedtke, Ronald Witteles, Vaishali Sanchorawala, Raphael Szalat, Heather J Landau, Erica Petrlik, Suzanne Lentzsch, Alexander Coltoff, Joan Bladé, M. Teresa Cibeira, Oliver C Cohen, Darren Foard, Julian D Gillmore, Helen J Lachmann, Ashutosh D. Wechalekar, Morie A. Gertz
Journal: Blood (2021)
Epinephrine before defibrillation in patients with shockable in-hospital cardiac arrest: propensity matched analysis
Authors: Erin Evans, Morgan B Swanson, Nicholas Mohr, Nassar Boulos, Mary Vaughan-Sarrazin, Paul S Chan, Saket Girotra
Journal: BMJ (2021)

Abstract Objective To determine the use of epinephrine (adrenaline) before defibrillation for treatment of in-hospital cardiac arrest due to a ventricular arrhythmia and examine its association with patient survival. Design Propensity matched analysis. Setting 2000-18 data from 497 hospitals participating in the American Heart Association’s Get With The Guidelines-Resuscitation registry. Participants Adults aged 18 and older with an index in-hospital cardiac arrest due to an initial shockable rhythm treated with defibrillation. Interventions Administration of epinephrine before first defibrillation. Main outcome measures Survival to discharge; favorable neurological survival, defined as survival to discharge with none, mild, or moderate neurological disability measured using cerebral performance category scores; and survival after acute resuscitation (that is, return of spontaneous circulation for &gt;20 minutes). A time dependent, propensity matched analysis was performed to adjust for confounding due to indication and evaluate the independent association of epinephrine before defibrillation with study outcomes. Results Among 34 820 patients with an initial shockable rhythm, 7054 (20.3%) were treated with epinephrine before defibrillation, contrary to current guidelines. In comparison with participants treated with defibrillation first, participants receiving epinephrine first were less likely to have a history of myocardial infarction or heart failure, but more likely to have renal failure, sepsis, respiratory insufficiency, and receive mechanical ventilation before in-hospital cardiac arrest (standardized differences &gt;10% for all). Treatment with epinephrine before defibrillation was strongly associated with delayed defibrillation (median 4 minutes v 0 minutes). In propensity matched analysis (6569 matched pairs), epinephrine before defibrillation was associated with lower odds of survival to discharge (22.4% v 29.7%; adjusted odds ratio 0.69; 95% confidence interval 0.64 to 0.74; P&lt;0.001), favorable neurological survival (15.8% v 21.6%; 0.68; 0.61 to 0.76; P&lt;0.001) and survival after acute resuscitation (61.7% v 69.5%; 0.73; 0.67 to 0.79; P&lt;0.001). The above findings were consistent in a range of sensitivity analyses, including matching according to defibrillation time. Conclusions Contrary to current guidelines that prioritize immediate defibrillation for in-hospital cardiac arrest due to a shockable rhythm, one in five patients are treated with epinephrine before defibrillation. Use of epinephrine before defibrillation was associated with worse survival outcomes.
Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease
Authors: Nadine Kaesler, Felix Schreibing, Thimoteus Speer, Sofia de la Puente-Secades, Nikolas Rapp, Christiane Drechsler, Nazanin Kabgani, Christoph Kuppe, Peter Boor, Vera Jankowski, Leon Schurgers, Rafael Kramann, Jürgen Floege
Journal: Kidney International (2021)
Impact of Pre-Graft Ruxolitinib on Post-Transplantation Outcome in Myelofibrosis Patients
Authors: Sara Villar, Sylvie Chevret, Xavier Poire, Amandine Charbonnier, Patrice Chevallier, Jean-Henri Bourhis, Edouard Forcade, Sylvain Chantepie, David Beauvais, Nicole Raus, Jacques-Olivier Bay, Michael Loschi, Raynier Devillier, Remy Duléry, Patrice Ceballos, Marie Thérèse Rubio, Yves Beguin, Stephanie Nguyen, Marie Robin
Journal: Blood (2021)
Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax
Authors: Hetalkumari Patel, Svea K. Wahlstrom, Maral DerSarkissian, Colin Kunzweiler, Felicia Castriota, Rose Chang, Hoi Ching Cheung, Yuqian Gu, Helen Guo, Mei Sheng Duh, Kellie J. Ryan
Journal: Blood (2021)
Intraoperative imaging in pathology-assisted surgery
Authors: Floris J. Voskuil, Jasper Vonk, Bert van der Vegt, Schelto Kruijff, Vasilis Ntziachristos, Pieter J. van der Zaag, Max J. H. Witjes, Gooitzen M. van Dam
Journal: Nature Biomedical Engineering (2021)
CD4-Targeted Fusosomes Are Capable of Transducing Resting T Helper Cells to Generate Highly Potent CAR-T Cells
Authors: Christie Ciarlo, Zach Frye, Andre DeGroot, Walter Flores, Kutlu Elpek, Lauren Pepper, Adam Johnson, Jagesh V Shah, Aaron E. Foster, Terry J. Fry
Journal: Blood (2021)
Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk
Authors: Tullio Palmerini, Antonio Giulio Bruno, Björn Redfors, Marco Valgimigli, Nevio Taglieri, Fausto Feres, Alexandre Abizaid, Ricardo Costa, Martine Gilard, Marie-Claude Morice, Myeong-Ki Hong, Byeong-Keuk Kim, Yangsoo Jang, Hyo-Soo Kim, Kyung Woo Park, Antonio Colombo, Alaide Chieffo, Masato Nakamura, Lak N. Kotinkaduwa, Elena Nardi, Francesco Saia, Mauro Gasparini, Giulia Rizzello, Giora Weisz, Ajay J. Kirtane, Roxana Mehran, Bernhard Witzenbichler, Nazzareno Galiè, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2021)
Possible Divergent Local and Peripheral Immunological Effects of Low-Dose Mesencure, an Enhanced Mesenchymal Cell Therapy, May Contribute to Its Success in Treating Severe Covid-19 Patients
Authors: Tomer Bronshtein, Dror Ben David, Atara Novak, Vered Kivity, Shai Meretzki, Tony Hayek, Shadi Hamoud, Nimrod Rozen
Journal: Blood (2021)
Genetic Landscape and Clonal Evolution Patterns of <i>CEBPA</i>-Mutated Acute Myeloid Leukaemia Based on Next-Generation Sequencing: A Retrospective Analysis
Authors: Livia Leuzzi, Valentina Mancini, Silvio Marco Veronese, Laura Pezzetti, Valentina Motta, Michele Nichelatti, Rosa Greco, Giambattista Bertani, Marco Montillo, Alessandro Beghini, Roberto Cairoli
Journal: Blood (2021)
Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab
Authors: Jacob N. Hall, Elizabeth Mormino, Amanda Ng, Athanasia Boumis, Jennifer L. Gaudioso, Guido A. Davidzon, Sharon J. Sha
Journal: JAMA Neurology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
C-MYC Augments the Proliferation and Survival of Hematopoietic Stem Cells and Multipotent Progenitors to Drive Myeloproliferative Neoplasms
Authors: Nicole D. Vincelette, Jungwon Moon, Andrew T. Kuykendall, Ling Zhang, Rami S. Komrokji, Daniel Murphy, John L. Cleveland, Seongseok Yun
Journal: Blood (2021)
Optimization of Robust Diagnostic Strategy for Patients with Fanconi Anaemia (FA)- an Indian Perspective
Authors: Gaurav Joshi, Nancy Beryl Janet, Vavish Ram, Vivek Gopalan, Thenral S G, Anurag Dutta Chaudhury, Debanjan Roy, Uday Prakash Kulkarni, Anup J Devasia, Fouzia N., Alok Srivastava, Biju George, Shaji Ramachandran Velayudhan
Journal: Blood (2021)
Gluten Intake and Risk of Digestive System Cancers in 3 Large Prospective Cohort Studies
Authors: Yiqing Wang, Yin Cao, Benjamin Lebwohl, Mingyang Song, Qi Sun, Peter H.R. Green, Edward L. Giovannucci, Walter C. Willett, Andrew T. Chan
Journal: Clinical Gastroenterology and Hepatology (2021)
Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for the Genetic Characterization of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) in Adults
Authors: Claudia Haferlach, Wencke Walter, Manja Meggendorfer, Anna Stengel, Constance Baer, Stephan Hutter, Niroshan Nadarajah, Heiko Müller, Wolfgang Kern, Torsten Haferlach
Journal: Blood (2021)
Abstract 9497: Dose Reduction of Ticagrelor in Ticagrelor Hyper-responders: A Pharmacokinetics and Pharmacodynamics (pkpd) Study
Authors: Ying ying Lin, Doreen Tan, CLIFF WONG, Alan Fong, LEE LEN TIONG, Teck Kee Ang, Patrick Zhan-Yun Lim, Michael Liang, Wan Xin Aw, Syed Imran
Journal: Circulation (2021)

Introduction: Ticagrelor has demonstrated superiority to Clopidogrel in reducing major adverse cardiovascular events, but at the cost of higher bleeding risk. However, the benefits were not replicated in the Asian trials, which demonstrated excess bleeding risk. We aimed to study the effect of Ticagrelor dose reduction in Ticagrelor hyper-responders, in addition to explore the effect of genotypes on Ticagrelor PKPD. Methods: ST-elevation myocardial infarction patients who undergone percutaneous coronary intervention and tested to be Ticagrelor hyper-responders defined as platelet reactivity of &lt;19U based on multiple electrode aggregometry ( MEA ), were recruited. Peak and trough concentration of Ticagrelor and its active metabolite AR-C124910XX, and platelet reactivity at the corresponding time points were measured when patients were on Ticagrelor 90 mg twice daily (BD) and again when reduced to Ticagrelor 45mg BD for at least 14 days. Platelet reactivity and plasma concentrations were measured using Multiplate ® Analyzer and liquid chromatography-mass spectrometry respectively. Results: Seventeen patients were recruited and 12 were reduced to Ticagrelor 45 mg BD. The mean age of the 12 patients was 55.92 (±9.41). Their average BMI was 25.33 (±4.24), there were 11 males, and comprised of 5 Chinese, 3 Malay, 3 Indian and 1 Eurasian. Plasma concentration (geometric mean) of parent Ticagrelor and its metabolite were 2-2.6 folds (p=0.002) higher at 90 mg compared to at 45 mg [C trough_Ticagrelor 267.22 ng/mL vs 131.83 ng/mL, C trough_metabolite 158.25 ng/mL vs 62.34 ng/mL, C peak_Ticagrelor 619.89 ng/mL vs 255.57 ng/mL and C peak_metabolite 236.21 ng/mL vs 91.64 ng/mL]. The mean MEA 45mg was 23U (±8) for trough 45mg . Even after dose reduction, all patients were still at “responder” MEA levels with responder MEA defined as MEA&lt;47U. CYP3A5*3 heterozygote was associated with higher peak 90mg and trough 90mg concentrations; p=0.037 and 0.025 respectively. Conclusions: Ticagrelor 45mg BD results in significantly lower serum levels but was still able to confer sufficient platelet inhibition. Larger studies should be conducted to correlate with clinical outcomes, and the impact of CYP3A5*3 on Ticagrelor response.
Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia
Authors: Brendan Beaton, Sarah C Sasson, Katherine Rankin, Juliette Raedemaeker, Alexander Wong, Priyanka Hastak, Andrew Warden, Alberto Ospina Stella, Anupriya Aggarwal, Ian D Caterson, Chansavath Phetsouphanh, Stuart Turville, Anthony D Kelleher, Fabienne Brilot, Judith Trotman
Journal: Blood (2021)
Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Authors: Matthew S. Davids, Ugochinyere Emeribe, Priyanka Gaitonde, Ling Cai
Journal: Blood (2021)
Notable Patterns in the Genomic Landscape of Adult T-Cell Leukemia/Lymphoma Encountered in HTLV-1 Endemic Western World Regions
Authors: Alejandro Ariel Gru, Caroline Snowden, Eli Williams, Carlos Barrionuevo, Jose Sanches, Maxime Battistella, Samuel Mo, Melissa Pulitzer, Govind Bhagat, Octavio Servitje, Denis Miyashiro, Fina Climent, Daniela Dueñas, Sandro Casavilca, KImberly Guyton-Ringbloom, Brady E Beltran, Denisse Castro, Ngoc L Toomey, Luciana Barreto, Eduardo Saul, Thomas Plate, Jennifer R Chapman, Jaehyuk Choi, Juan Carlos Ramos
Journal: Blood (2021)
Noninvasive detection of spatiotemporal activation-repolarization interactions that prime idiopathic ventricular fibrillation
Authors: Matthijs J. M. Cluitmans, Laura R. Bear, Uyên C. Nguyên, Bianca van Rees, Job Stoks, Rachel M. A. ter Bekke, Casper Mihl, Jordi Heijman, Kevin D. Lau, Edward Vigmond, Jason Bayer, Charly N. W. Belterman, Emma Abell, Louis Labrousse, Julien Rogier, Olivier Bernus, Michel Haïssaguerre, Rutger J. Hassink, Rémi Dubois, Ruben Coronel, Paul G. A. Volders
Journal: Science Translational Medicine (2021)

Premature beats originating in clinically concealed areas of local early repolarization promote ventricular arrhythmias and sudden cardiac arrest.
In-Home Care at the End of Life—How Much Is Needed?
Authors: Meera R. Agar
Journal: JAMA Network Open (2021)

We spend a large proportion of our lives in our home environment, so on face value it is a natural assumption to consider dying at home an important goal for quality end-of-life care. 1 As the need for care at the end of life grows in the face of an aging population, understanding how best to configure and fund services for people approaching the end of life is increasingly important.It requires consideration of what outcomes we are aiming to achieve and for whom (the patient, their carer,
Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain
Authors: Mi Kwon, Gloria Iacoboni, Juan Luis Reguera, Lucia Lopez Corral, Rafael Hernani, Manuel Guerreiro, Ana Carolina Caballero, Valentín Ortiz-Maldonado, Jose M. Sanchez, Annalisa Paviglianiti, Juan-Manuel Sancho, Mariana Bastos-Oreiro, Gillen Oarbeascoa, Reyes Maria Martin Rojas, Eva Catala, Javier Delgado Serrano, Alberto Mussetti, Jaime Sanz, Maria Calbacho, Rebeca Bailen, Javier Briones, Juan Carlos Hernandez Boluda, Alejandro Martin Garcia-Sancho, Jose L. Diez-Martin, Pere Barba
Journal: Blood (2021)